Nifty

:

15746.45

Sensex

:

52578.76

-78.00 (-0.49%)
-316.65 (-0.60%)

Login

Nifty
Sensex

:
:

15746.45
52578.76

-78.00 (-0.49%)
-316.65 (-0.60%)

Gufic Biosciences Ltd.

Pharmaceuticals & Drugs - Domestic

Rating :

64/99

BSE: 509079 | NSE: GUFICBIO

Watchlist

NSE BSE

187.30

27-Jul-2021

Open
High
Low
Previous Close

184.25
192.30
184.25
184.25

Volume
Traded Value (lacs)
52 Week High
52 Week Low

508812
963.57
215.95
76.20

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

1,817.71
41.10
1

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

1,917.62
0.05%
10.48

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

17.48
12.09
5.39

EBITDA CAGR (%)

10 Years
5 Years
3 Years

21.93
17.75
2.83

PAT CAGR (%)

10 Years
5 Years
3 Years

31.67
25.58
11.53

P:E (Median)

8 Years
5 Years
3 Years

35.64
39.03
30.85

P:BV (Average)

8 Years
5 Years
3 Years

7.72
7.72
7.72

EV:EBITDA (Average)

8 Years
5 Years
3 Years

16.19
18.33
16.02

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated

Description Mar 21 Mar 20 Var% Dec 20 Dec 19 Var% Sep 20 Sep 19 Var% Jun 20 Jun 19 Var%
Net Sales 131.93 87.07 51.52% 144.41 97.74 47.75% 120.35 86.03 39.89% 54.14 92.39 -41.40%
Expenses 108.18 74.68 44.86% 119.94 85.81 39.77% 94.72 75.83 24.91% 54.74 80.25 -31.79%
EBITDA 23.75 12.39 91.69% 24.47 11.93 105.11% 25.62 10.19 151.42% -0.59 12.14 -
EBIDTM 18.00% 14.23% 16.94% 12.20% 21.29% 11.85% -1.10% 13.14%
Other Income 0.66 1.27 -48.03% 0.60 3.06 -80.39% 2.25 1.61 39.75% 0.99 1.02 -2.94%
Interest 2.87 3.62 -20.72% 3.68 3.45 6.67% 3.39 3.50 -3.14% 3.22 2.77 16.25%
Depreciation 4.48 3.75 19.47% 3.22 2.11 52.61% 2.48 2.65 -6.42% 2.28 1.20 90.00%
PBT 17.05 6.29 171.07% 18.17 9.42 92.89% 22.01 5.65 289.56% -5.11 9.19 -
Tax 4.18 1.31 219.08% 4.99 2.40 107.92% 5.68 1.35 320.74% -1.36 2.38 -
PAT 12.87 4.97 158.95% 13.18 7.02 87.75% 16.33 4.30 279.77% -3.75 6.81 -
PATM 9.76% 5.71% 9.13% 7.18% 13.57% 5.00% -6.92% 7.37%
EPS 1.33 0.51 160.78% 1.36 0.72 88.89% 1.69 0.44 284.09% -0.39 0.70 -

Description Mar 21 Mar 20 Var% Dec 20 Dec 19 Var% Sep 20 Sep 19 Var% Jun 20 Jun 19 Var%
Net Sales 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Expenses 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
EBITDA 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
EBIDTM 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Other Income 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Interest 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Depreciation 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PBT 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Tax 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PAT 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PATM 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0

Annual Results

Standalone Figures in Rs. Crores

Right to Left

Description TTM Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Net Sales 450.83 357.75 350.77 305.58 245.52 202.20 151.55 123.01 100.14 83.57 71.47 Net Sales Growth 24.12% 1.99% 14.79% 24.46% 21.42% 33.42% 23.20% 22.84% 19.83% 16.93% Cost Of Goods Sold 240.37 157.45 161.37 128.58 107.42 90.84 73.47 55.61 46.05 40.87 32.80 Gross Profit 210.46 200.30 189.40 177.01 138.10 111.35 78.08 67.40 54.09 42.70 38.66 GP Margin 46.68% 55.99% 54.00% 57.93% 56.25% 55.07% 51.52% 54.79% 54.01% 51.09% 54.09% Total Expenditure 377.58 313.17 304.78 266.80 222.57 182.51 137.28 110.98 89.40 76.23 65.33 Power & Fuel Cost - 4.50 3.43 3.58 3.51 3.57 3.16 2.95 3.21 2.50 2.13 % Of Sales - 1.26% 0.98% 1.17% 1.43% 1.77% 2.09% 2.40% 3.21% 2.99% 2.98% Employee Cost - 51.57 46.85 44.62 41.03 31.95 19.23 12.25 5.45 4.37 3.96 % Of Sales - 14.42% 13.36% 14.60% 16.71% 15.80% 12.69% 9.96% 5.44% 5.23% 5.54% Manufacturing Exp. - 44.35 43.16 37.69 28.94 23.54 15.48 17.33 9.14 7.49 7.21 % Of Sales - 12.40% 12.30% 12.33% 11.79% 11.64% 10.21% 14.09% 9.13% 8.96% 10.09% General & Admin Exp. - 30.52 32.32 31.50 27.03 20.56 13.56 8.82 3.79 4.96 4.06 % Of Sales - 8.53% 9.21% 10.31% 11.01% 10.17% 8.95% 7.17% 3.78% 5.94% 5.68% Selling & Distn. Exp. - 16.07 11.36 13.26 9.11 8.19 8.78 12.41 19.92 15.85 14.91 % Of Sales - 4.49% 3.24% 4.34% 3.71% 4.05% 5.79% 10.09% 19.89% 18.97% 20.86% Miscellaneous Exp. - 8.71 6.29 7.57 5.53 3.85 3.61 1.61 1.84 0.18 14.91 % Of Sales - 2.43% 1.79% 2.48% 2.25% 1.90% 2.38% 1.31% 1.84% 0.22% 0.38% EBITDA 73.25 44.58 45.99 38.78 22.95 19.69 14.27 12.03 10.74 7.34 6.14 EBITDA Margin 16.25% 12.46% 13.11% 12.69% 9.35% 9.74% 9.42% 9.78% 10.72% 8.78% 8.59% Other Income 4.50 6.82 4.17 2.86 1.44 0.66 0.57 0.63 0.39 0.37 0.16 Interest 13.16 12.72 10.16 8.88 6.34 6.20 4.46 3.92 3.69 2.85 2.12 Depreciation 12.46 8.35 4.65 4.40 3.68 3.79 3.85 2.47 2.18 1.88 1.81 PBT 52.12 30.33 35.35 28.37 14.37 10.36 6.53 6.27 5.26 2.97 2.37 Tax 13.49 7.47 13.41 13.48 5.35 3.03 2.37 2.01 1.93 1.44 0.91 Tax Rate 25.88% 24.63% 37.93% 44.99% 37.23% 29.25% 36.29% 32.06% 36.69% 48.48% 38.40% PAT 38.63 22.86 21.94 16.48 9.02 7.32 4.16 4.26 3.33 1.53 1.46 PAT before Minority Interest 38.63 22.86 21.94 16.48 9.02 7.32 4.16 4.26 3.33 1.53 1.46 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 8.57% 6.39% 6.25% 5.39% 3.67% 3.62% 2.74% 3.46% 3.33% 1.83% 2.04% PAT Growth 67.23% 4.19% 33.13% 82.71% 23.22% 75.96% -2.35% 27.93% 117.65% 4.79% EPS 3.99 2.36 2.26 1.70 0.93 0.76 0.43 0.44 0.34 0.16 0.15

Results Balance Sheet

Standalone Figures in Rs. Crores

Right to Left

Description Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Shareholder's Funds 95.85 75.35 54.14 37.33 33.96 27.10 26.21 22.39 19.51 18.44 Share Capital 7.78 7.78 7.78 7.74 7.74 7.74 7.74 7.74 7.74 7.74 Total Reserves 88.07 67.56 46.35 29.59 26.22 19.36 18.47 14.66 11.78 10.70 Non-Current Liabilities 35.38 17.16 12.54 9.16 14.56 16.58 24.63 23.53 8.75 9.71 Secured Loans 17.90 11.25 4.43 3.20 4.84 8.62 10.17 13.72 1.65 2.25 Unsecured Loans 0.03 0.06 3.89 3.42 2.82 2.88 4.71 4.72 2.67 3.08 Long Term Provisions 6.95 1.86 2.26 2.29 1.39 1.41 1.35 1.19 1.00 0.77 Current Liabilities 260.15 217.72 168.55 128.18 103.68 83.61 60.31 43.65 47.06 35.41 Trade Payables 108.62 77.81 75.98 43.74 52.62 49.53 31.80 20.14 22.22 14.64 Other Current Liabilities 16.45 16.28 17.24 20.75 14.10 13.01 11.28 7.74 6.42 3.48 Short Term Borrowings 89.43 84.69 69.17 46.97 32.28 17.90 14.77 13.74 15.32 13.11 Short Term Provisions 45.64 38.95 6.16 16.73 4.67 3.16 2.47 2.04 3.10 4.17 Total Liabilities 391.38 310.23 235.23 174.67 152.20 127.29 111.15 89.57 75.32 63.56 Net Block 41.64 24.45 22.85 21.96 22.15 25.11 30.23 26.83 17.71 17.32 Gross Block 62.72 37.19 31.00 25.65 51.31 50.81 48.46 42.59 31.60 29.41 Accumulated Depreciation 21.07 12.74 8.15 3.68 29.17 25.71 18.23 15.76 13.89 12.09 Non Current Assets 92.32 46.34 37.02 31.42 32.69 35.81 41.84 39.36 24.33 22.16 Capital Work in Progress 30.61 9.63 2.05 0.04 0.00 0.00 0.00 2.98 1.07 0.00 Non Current Investment 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 Long Term Loans & Adv. 18.23 10.16 8.73 7.60 9.01 9.17 11.32 7.34 5.49 4.77 Other Non Current Assets 1.84 2.09 3.38 1.82 1.52 1.52 0.28 2.20 0.05 0.06 Current Assets 299.06 263.89 198.20 143.25 119.51 91.48 69.30 50.22 50.99 41.40 Current Investments 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 109.20 94.28 94.20 63.02 50.26 36.80 26.12 20.00 16.91 12.77 Sundry Debtors 101.24 103.18 80.80 52.12 56.23 33.38 28.21 20.01 22.57 17.64 Cash & Bank 10.82 7.59 7.50 5.64 6.16 6.21 2.54 1.28 0.96 0.95 Other Current Assets 77.81 1.10 0.38 1.09 6.86 15.08 12.44 8.93 10.55 10.05 Short Term Loans & Adv. 74.28 57.74 15.33 21.38 6.10 12.45 9.60 7.19 10.22 9.79 Net Current Assets 38.91 46.17 29.66 15.07 15.84 7.87 8.99 6.57 3.93 5.99 Total Assets 391.38 310.23 235.22 174.67 152.20 127.29 111.14 89.58 75.32 63.56

Cash Flow

Standalone Figures in Rs. Crores

Right to Left

Description Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Cash From Operating Activity 45.69 5.21 -4.82 -4.13 -4.32 11.15 10.87 5.26 5.16 1.04 PBT 30.33 35.35 29.95 14.37 11.19 6.53 6.27 5.26 2.97 2.37 Adjustment 18.26 13.35 12.07 9.75 8.84 8.19 6.27 5.95 4.86 3.84 Changes in Working Capital 7.06 -33.52 -30.40 -23.70 -21.31 -1.60 -0.19 -4.42 -1.87 -4.45 Cash after chg. in Working capital 55.66 15.18 11.63 0.42 -1.28 13.12 12.36 6.79 5.97 1.76 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -9.96 -9.98 -16.44 -4.55 -2.65 -1.96 -1.49 -1.54 -0.80 -0.72 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 -0.38 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -42.44 -12.99 -8.84 -4.69 -0.51 -2.39 -2.78 -13.26 -3.33 -2.03 Net Fixed Assets -46.51 -13.77 -7.36 25.62 -0.50 -2.35 -2.89 -12.90 -3.26 -1.99 Net Investments 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Others 4.07 0.78 -1.48 -30.31 -0.01 -0.04 0.11 -0.36 -0.07 -0.04 Cash from Financing Activity -2.73 7.71 14.40 7.41 4.78 -5.09 -6.82 8.32 -1.82 0.86 Net Cash Inflow / Outflow 0.52 -0.08 0.75 -1.41 -0.05 3.67 1.26 0.32 0.02 -0.13 Opening Cash & Equivalents 3.66 3.74 2.99 4.28 6.21 2.54 1.28 0.96 0.95 1.08 Closing Cash & Equivalent 4.18 3.66 3.74 2.87 6.16 6.21 2.54 1.28 0.96 0.95

Financial Ratios

Standalone

Right to Left

Description Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Book Value (Rs.) 12.32 9.68 6.96 4.83 4.39 3.50 3.39 2.90 2.52 2.38 ROA 6.52% 8.04% 8.04% 5.52% 5.24% 3.49% 4.25% 4.04% 2.20% 2.46% ROE 26.70% 33.89% 36.03% 25.31% 23.99% 15.60% 17.55% 15.89% 8.05% 8.17% ROCE 22.67% 29.65% 34.10% 24.26% 24.24% 18.38% 17.45% 18.44% 15.02% 12.43% Fixed Asset Turnover 7.41 10.57 11.21 6.77 4.19 3.22 2.86 2.85 2.83 2.71 Receivable days 100.73 93.16 76.39 75.93 76.38 70.29 67.55 73.52 84.97 80.78 Inventory Days 100.27 95.44 90.36 79.39 74.21 71.80 64.60 63.71 62.71 57.14 Payable days 115.28 115.32 80.93 87.99 110.87 119.47 95.34 87.64 91.90 77.66 Cash Conversion Cycle 85.71 73.27 85.82 67.32 39.73 22.62 36.81 49.59 55.78 60.27 Total Debt/Equity 1.16 1.30 1.47 1.52 1.26 1.21 1.27 1.55 1.05 1.04 Interest Cover 3.38 4.48 4.37 3.27 2.67 2.46 2.60 2.43 2.04 2.12

Top Investors:

vipula jayesh choksi

sbi healthcare opportunities fund

jagdish n. master

Annual Reports:

News Update:

Gufic Biosciences gets permission to manufacture, market Liposomal Amphotericin B Injection
21st May 2021, 11:14 AM

The said injection is used to treat cases of Mucormycosis, also called as Black Fungus that damages the nose, eyes, sinuses, and sometimes even the brain
Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

Feedback